Company / Cash & Equivalents
CorVel Corporation Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$170.6M
FY2025
5-year range
$71.3M / $170.6M
FY2021-FY2025
Trend
+61.6%
vs FY2024
Sector context
#90 of 152
Health Care
What the data says
At $171M, CorVel Corporation's cash & equivalents ranks #90 of 152 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $29M in FY2017 to $171M in FY2025.
Based on SEC 10-K filings.
$171M in FY2025 with a 5-year CAGR of +15.4%.
Improved from $71M to $171M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +20.5%
- 5-Year CAGR
- +15.4%
- 10-Year CAGR
- -
Sector benchmark
#90 of 152 in Health CareTop 59% of 152This company $170.6M Sector average $1.2B
▼
-85.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +15.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 61.6% year-over-year.
- Ranks #90 out of 152 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $170.6M | +61.6% |
| FY2024 | $105.6M | +48.0% |
| FY2023 | $71.3M | -26.8% |
| FY2022 | $97.5M | -30.2% |
| FY2021 | $139.7M | +67.9% |
| FY2020 | $83.2M | -9.3% |
| FY2019 | $91.7M | +64.4% |
| FY2018 | $55.8M | +94.9% |
| FY2017 | $28.6M | -12.7% |
| FY2016 | $32.8M | +28.5% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026